New drug YL202 takes on tough lung and breast cancers
NCT ID NCT05653752
First seen May 29, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called YL202 in about 80 adults with advanced lung or breast cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Participants will receive YL202 and be closely monitored for side effects and how the drug moves through their body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BRCR Global
Plantation, Florida, 33322, United States
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jilin Provincial Cancer Hospital
Changchun, Jilin, 130012, China
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Next Oncology-Dallas
Irving, Texas, 75039, United States
-
Next Oncology-Virginia
Fairfax, Virginia, 22031, United States
-
Summit Cancer Center
Spokane Valley, Washington, 99216, United States
-
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, 317099, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UT health east Texas HOPE Cancer Center
Tyler, Texas, 75701, United States
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.